Page 11 - Vaccine Development Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana

5% Below are specific updates on pipeline assets since our previous earnings announcement on October 27, 2020: Abrocitinib (PF-04965842) — In November 2020, Pfizer announced positive top-line results from the fifth Phase 3 trial of abrocitinib, JADE REGIMEN, a 52-week study which investigated abrocitinib in patients 12 and older with moderate to severe atopic dermatitis (AD) following response to initial open label induction treatment with abrocitinib 200 mg. Patients were randomized into one of three arms: 200 mg, 100 mg or placebo. Both doses of abrocitinib met the primary endpoint, resu...

TMCnet News Generex and NuGenerex Immuno-Oncology Provide Update on Ii-Key COVID-19 Vaccine Development Program and Files Trademark Application for The Complete Vaccine™ [December 31, 2020] Generex and NuGenerex Immuno-Oncology Provide Update on Ii-Key COVID-19 Vaccine Development Program and Files Trademark Application for The Complete Vaccine™ The trademark application can be found at USPTO.gov by searching “Complete Vaccine” in the Trademark Electronic Search System (TESS) Ii-Key-SARS-CoV-2 vaccine enters GMP production for clinical supply Ii-Key epitopes selected that elicit...

NAIROBI, Dec. 10 (Xinhua) -- African governments should embark on proactive engagement with local communities to boost uptake of COVID-19 vaccine once they are deployed in the continent, a senior World Health Organization (WHO) official said on Thursday.